Glaucoma

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

The medical technology company ViaLase will reveal the 2-year data from their FLigHT clinical study as well as give additional information about their pipeline at ASCRS 2023.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.

Physicians should continue to have conversations and assessments of patients with glaucoma before the decision is reached to stop driving.

A look back on what happened in optometry during the week of March 10-March 16.

Empowering individuals to take greater ownership of their visual health.

This recall is being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of brimonidine tartrate ophthalmic solution bottles

Supplementing vision care with nutrition may protect ocular tissues.

A look back on what's happened in optometry during the week of February 11-February 16.

Medical and surgical technological advances show promise for future glaucoma management.

A look back on what's happened in optometry during the week of February 4-February 9.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

Shan Lin, MD, gives key takeaways from his G360 presentation, "The latest in IOLs: When and how to use them?"

Robert Stamper, MD, gives key takeaways from his G360 presentation, "Home tonometry: Worth the pressure?"

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

A look back on what's happened in optometry during the week of Jan. 28-Feb. 2.

Researchers found that the use of atropine drops after glaucoma surgery may impact vision and prolong rehabilitation time.

A look back on what's happened in optometry during the week of Jan. 21-Jan. 26.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

The 'Screen, Protect, Cure' campaign aims to education individuals who may be at risk for glaucoma, while raising funding for glaucoma research during Glaucoma Awareness Month.

One individual’s habit can be the demise of good health.

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

A meditation on the effects of putting off doctors' orders.

Austin Lifferth, OD, FAAO, shares highlights from his AAOpt 2022 presentations, including a triad approach to evaluating the optic nerve in glaucoma, and recentering glaucoma care with these 5 GlaucoMantras.

Researchers reported that the preclinical detectable phase for OAG is about 10 years.